Northside Hospital - Duluth

Futó vizsgálatok

• Toboroz

  Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  NCT06931340· 3. fázis· Forrás

• Toboroz

  Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  NCT06616584· 2/3. fázis· Forrás

• Toboroz

  Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  NCT06418204· Forrás

• Toboroz

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· 2/3. fázis· Forrás

• Toboroz

  LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

  NCT06073431· Forrás

• Toboroz

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· 3. fázis· Forrás

• Toboroz

  Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

  NCT05812807· 3. fázis· Forrás

• Toboroz

  Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  NCT05642572· 2. fázis· Forrás

• Fut, nem toboroz

  Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

  NCT05633602· 3. fázis· Forrás

• Toboroz

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· 2/3. fázis· Forrás

• Fut, nem toboroz

  Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT05096663· 2/3. fázis· Forrás

• Fut, nem toboroz

  Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT04625647· 2. fázis· Forrás

• Fut, nem toboroz

  Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

  NCT04462406· 2. fázis· Forrás

• Toboroz

  Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  NCT04267848· 3. fázis· Forrás

• Fut, nem toboroz

  Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

  NCT04268550· 2. fázis· Forrás

• Fut, nem toboroz

  Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

  NCT03793166· 3. fázis· Forrás

• Fut, nem toboroz

  Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

  NCT03793179· 3. fázis· Forrás

• Toboroz

  Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445· 2/3. fázis· Forrás

• Fut, nem toboroz

  Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

  NCT03244384· 3. fázis· Forrás

• Fut, nem toboroz

  Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

  NCT02954874· 3. fázis· Forrás

• Fut, nem toboroz

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

  NCT02339571· 2/3. fázis· Forrás

• Fut, nem toboroz

  Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781· 3. fázis· Forrás

• Fut, nem toboroz

  Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060· 2. fázis· Forrás

• Fut, nem toboroz

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· 3. fázis· Forrás

• Fut, nem toboroz

  Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282· 3. fázis· Forrás

• Fut, nem toboroz

  Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák6 toboroz
• Vastagbélrák3 toboroz
• Hasnyálmirigyrák1 toboroz
• Hólyagrák1 toboroz
• Melanóma1 toboroz
• Petefészekrák1 toboroz
• Prosztatarák1 toboroz
• Tripla negatív emlőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

  NCT04173507· 2. fázis· Forrás

• Leállították

  Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

  NCT03737994· 2. fázis· Forrás

• Lezárult

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· 2. fázis· Forrás

• Lezárult

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· 2. fázis· Forrás

• Leállították

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· 3. fázis· Forrás

• Lezárult

  Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

  NCT03475186· 2. fázis· Forrás

• Lezárult

  The National Myelodysplastic Syndromes (MDS) Study

  NCT02775383· Forrás